These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21416470)

  • 1. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer.
    Yin M; Li C; Li X; Lou G; Miao B; Liu X; Meng F; Zhang H; Chen X; Sun M; Ling Q; Zhou R
    J Surg Oncol; 2011 Jul; 104(1):29-36. PubMed ID: 21416470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
    Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
    Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
    Tsiatas ML; Gyftaki R; Liacos C; Politi E; Rodolakis A; Dimopoulos MA; Bamias A
    Int J Gynecol Cancer; 2009 Nov; 19(8):1329-34. PubMed ID: 20009885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
    Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
    Davidson B; Alejandro E; Flørenes VA; Goderstad JM; Risberg B; Kristensen GB; Trope CG; Kohn EC
    Cancer; 2004 May; 100(10):2139-47. PubMed ID: 15139056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
    Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
    J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
    Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
    Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
    Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
    Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer.
    Nomura H; Tsuda H; Susumu N; Fujii T; Banno K; Kataoka F; Tominaga E; Suzuki A; Chiyoda T; Aoki D
    Int J Gynecol Cancer; 2010 Apr; 20(3):341-5. PubMed ID: 20375794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
    Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
    Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
    Bagnoli M; Ambrogi F; Pilotti S; Alberti P; Ditto A; Barbareschi M; Galligioni E; Biganzoli E; Canevari S; Mezzanzanica D
    Endocr Relat Cancer; 2009 Jun; 16(2):443-53. PubMed ID: 19321593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yildirim Y; Ertas IE; Dogan A; Gultekin OE; Gultekin E
    J Surg Oncol; 2012 Feb; 105(2):200-5. PubMed ID: 21815151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
    Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
    Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
    Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
    Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
    Yigit S; Demir L; Tarhan MO; Cabuk FK; Ellidokuz H; Erten C; Somali I; Dirican A; Cakalagaoglu F
    Neoplasma; 2012; 59(5):475-85. PubMed ID: 22668011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma.
    Turunen M; Talvensaari-Mattila A; Soini Y; Santala M
    Anticancer Res; 2009 Dec; 29(12):5185-9. PubMed ID: 20044634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hospitalizations associated with adverse effects of chemotherapy in a large community-based cohort of elderly women with ovarian cancer.
    Nurgalieva Z; Liu CC; Du XL
    Int J Gynecol Cancer; 2009 Nov; 19(8):1314-21. PubMed ID: 20009883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.